IRIS
COSTANTINI, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.363
EU - Europa 2.646
AS - Asia 2.580
SA - Sud America 612
Continente sconosciuto - Info sul continente non disponibili 207
AF - Africa 115
OC - Oceania 29
Totale 12.552
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.157
SG - Singapore 827
IT - Italia 655
CN - Cina 533
VN - Vietnam 519
BR - Brasile 469
RU - Federazione Russa 414
UA - Ucraina 315
SE - Svezia 251
HK - Hong Kong 236
DE - Germania 206
IE - Irlanda 186
FR - Francia 172
GB - Regno Unito 110
BD - Bangladesh 101
DK - Danimarca 96
FI - Finlandia 90
CA - Canada 82
TR - Turchia 81
IN - India 62
KR - Corea 56
AR - Argentina 53
NL - Olanda 53
CI - Costa d'Avorio 39
MX - Messico 32
AU - Australia 27
CO - Colombia 26
EC - Ecuador 24
JP - Giappone 22
AT - Austria 21
IQ - Iraq 21
ID - Indonesia 17
ZA - Sudafrica 17
GT - Guatemala 15
PL - Polonia 15
SV - El Salvador 15
MA - Marocco 14
VE - Venezuela 14
CR - Costa Rica 13
EG - Egitto 12
BE - Belgio 11
ES - Italia 11
PY - Paraguay 11
AE - Emirati Arabi Uniti 10
PK - Pakistan 10
UZ - Uzbekistan 10
IL - Israele 9
KE - Kenya 9
PR - Porto Rico 9
HN - Honduras 8
JM - Giamaica 8
TN - Tunisia 8
CL - Cile 7
MY - Malesia 7
PH - Filippine 7
CH - Svizzera 6
JO - Giordania 6
KZ - Kazakistan 6
LT - Lituania 6
NP - Nepal 6
RO - Romania 6
SA - Arabia Saudita 6
TH - Thailandia 6
TT - Trinidad e Tobago 6
AL - Albania 5
AZ - Azerbaigian 5
DO - Repubblica Dominicana 5
DZ - Algeria 5
NI - Nicaragua 5
CW - ???statistics.table.value.countryCode.CW??? 4
GP - Guadalupe 4
BG - Bulgaria 3
BO - Bolivia 3
UY - Uruguay 3
AM - Armenia 2
EE - Estonia 2
GA - Gabon 2
HR - Croazia 2
KW - Kuwait 2
LB - Libano 2
NG - Nigeria 2
NO - Norvegia 2
OM - Oman 2
PA - Panama 2
PS - Palestinian Territory 2
TW - Taiwan 2
BB - Barbados 1
BF - Burkina Faso 1
BJ - Benin 1
BS - Bahamas 1
CD - Congo 1
CG - Congo 1
CZ - Repubblica Ceca 1
EU - Europa 1
FJ - Figi 1
GY - Guiana 1
HU - Ungheria 1
IR - Iran 1
IS - Islanda 1
KG - Kirghizistan 1
Totale 12.337
Salva come PNG Salva come JPEG
Città #
Ashburn 1.131
Singapore 471
Dallas 463
Chandler 376
Jacksonville 319
Council Bluffs 296
San Jose 276
Fairfield 247
Hong Kong 230
Boardman 187
Dublin 181
Ho Chi Minh City 171
New York 163
Wilmington 145
Beijing 132
Des Moines 128
Los Angeles 115
Woodbridge 114
Hanoi 107
Seattle 103
Ann Arbor 85
Houston 85
Lauterbourg 82
Rome 77
The Dalles 74
Princeton 73
San Mateo 73
Lawrence 71
Redmond 58
Milan 55
Moscow 55
Hefei 53
Cambridge 50
São Paulo 46
Chicago 42
Centro 40
San Diego 40
Santa Clara 40
Abidjan 39
Orem 39
Da Nang 36
Phoenix 35
Ancona 33
Buffalo 33
Munich 32
Helsinki 29
Denver 26
London 25
Haiphong 23
Guangzhou 21
Marche 21
San Francisco 20
Atlanta 17
Chennai 17
Rio de Janeiro 17
Turin 17
Montreal 16
Turku 16
Florence 15
Melbourne 15
Norwalk 14
Shanghai 14
Tokyo 14
Toronto 14
Biên Hòa 13
San Salvador 13
Amsterdam 12
Brooklyn 12
Charlotte 12
Frankfurt am Main 12
Guatemala City 12
Guayaquil 12
Istia D'ombrone 12
Johannesburg 12
Warsaw 12
Washington 12
Wuhan 12
Bogotá 11
Brussels 11
Columbus 11
San José 11
Naples 10
Paris 10
Salt Lake City 10
Tashkent 10
Boston 9
Brookline 9
Civitanova Marche 9
Dhaka 9
Hải Dương 9
Istanbul 9
Miami 9
Nuremberg 9
Porto 9
Quanzhou 9
Belo Horizonte 8
Bologna 8
Buenos Aires 8
Chiaravalle 8
Elk Grove Village 8
Totale 7.424
Salva come PNG Salva come JPEG
Nome #
Specific Anti-Nuclear Antibodies, Clinical Features and Outcome Following Treatment with Nilotinib In Patients with Chronic Graft-Versus-Host Disease. The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Poster Sessions 329
A novel method to evaluate prethawing viability of cryopreserved CD34+ hematopoietic stem cells for autologous transplantation. 235
Late or missed HIV diagnosis during pregnancy is still occurring in a high-income country and represents a high risk of MTCT 200
A new method to assess the viability of collected CD34+ cells before reinfusion: a prospective study in 50 autotransplanted patients. 198
Immunomodulatory Effects of Tyrosine Kinase Inhibitor In Vitro and In Vivo Study 198
Tollerabilità metabolica e durevolezza degli schemi antiretrovirali comprendenti nevirapina (Durability and tolerability of long-term nevirapine-based HAART). 193
Cost of HAART in Italy: multicentric evaluation and determinants from a large HIV outpatient cohort. 191
Gut epithelial impairment, microbial translocation and immune system activation in inflammatory bowel disease–associated spondyloarthritis 191
Abnormalities of erythropoiesis during HIV-1 disease: a longitudinal analysis. 185
In vitro comparison of different TKI activity in T-Cell populations: selective sparing of Treg by Nilotinib. 184
Age-related M1/M2 phenotype changes in circulating monocytes from healthy/unhealthy individuals 184
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy 181
Quantification of the HIV-1 total reservoir in the peripheral blood of naïve and treated patients by a standardised method derived from a commercial HIV-1 RNA quantification assay. 181
Nilotinib Treatment of Patients Affected by Chronic Graft-versus-Host Disease Reduces Collagen Production and Skin Fibrosis by Downmodulating the TGF-β and p-SMAD Pathway 180
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting 176
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 172
Higly active antiretroviral therapy induces specific changes in effector and central memory T cell sub-populations 163
Activated switched memory B cell clusters in chronic spontaneous urticaria are increased in subjects with long disease duration and relapse upon omalizumab discontinuation: Results of the IL-10-OMZ study 158
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV. 157
Diagnosi sierologica nelle malattie autoimmuni non organo-specifiche. 154
Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy. 152
Direct acting antivirals (DAAs) for the treatment of HCV infection in HIV/HCV coinfected patients: a clinical experience. 151
OC-34 Clinical outcome of switching to a dual drug regimen (2DR) vs. switching or remaining on a triple (3DR) regimen in the setting of a viral load ≤50 copies/mL 150
POOR RESPONSE TO FIRST BNT162B2 SARS-COV-2 VACCINE DOSE IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT 149
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI. 147
OC-43 ‘U=U impossibile sbagliare’ awareness campaign: impact assessment among PLWH 146
Response to: Letter to the Editor on “Bonafè M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine Growth Factor Rev” by Eugenia Quiros-Roldan, Giorgio Biasiotto and Isabella Zanella 146
Effects of cryopreservation on lymphocyte immunophenotype and function 145
Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. 142
Comparsa di polmonite in soggetto con storia recente di inappetenza, disfagia, calo ponderale, ed eritema diffuso. 141
CROI 2013: le ricadute per la pratica clinica. 138
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 137
Characterisation and outcomes of difficult-to-treat patients in an Italian cohort of PLWHIV starting modern ART regimens. 135
PROGETTO E-PROs: COSTRUZIONE DI UNA PIATTAFORMA DIGITALE PER LA GESTIONE DI STRUMENTI CENTRATI SUL PAZIENTE NELLA PRATICA CLINICA (The E-PROs Project: creation of a digital platform to manage patient-oriented tools in clinical practice). 134
Day-On, Day-Off emtricitabine, tenofovir disoproxil fumarate and efavirenz single tablet regimen (DODO) as maintenance therapy in HIV-infected patients 133
SARS-CoV-2 mRNA Vaccine Response in People Living with HIV According to CD4 Count and CD4/CD8 Ratio 132
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. 131
Il ruolo del Medico di Medicina Generale nella diagnosi precoce della malattia da HIV. 129
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50cp/mL. 128
P131 Anlaids community-based HIV screening as a tool to improve HIV diagnosis among asymptomatic individuals 127
Efficacy and costs of Direct Acting Antivirals (DAAS) for the treatment of HCV Iinfection amnog HCV-monoinfected and HIV/HCV co-infected patients in real-life setting 126
OC52 Long-term effectiveness of bictegravir-emtricitabine-tenofovir alafenamide (B/F/TAF) as first-line therapy and as switch strategy in virologically suppressed persons with HIV up to 192-weeks: data from the ICONA-BIC Study 124
Do we still need CD4 T cell count? 124
Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. 124
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 123
The effect of dupilumab in an HBV-HIV coinfected atopic patient: a case report 123
Molecular analysis of hepatitis B virus (HBV) in an HIV co-infected patient with reactivation of occult HBV infection following discontinuation of lamivudine-including antiretroviral therapy. 122
Humoral and cellular immunity after mRNA COVID-19 vaccine in psoriatic patients on biological or immunosuppressive therapy: a real-life experience 121
Genotypic Resistance Tests for the Management of Structured Therapeutic Interruptions after Multiple Drug Failure: Prosecution 121
SC6 Promoting hepatitis and HIV screening in high prevalence populations: the ‘test in the city’ project 120
Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort 120
Validation of a self-reported HIV symptoms list: the ISS-HIV symptoms scale. 119
Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay. 117
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 117
Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort study. 117
ORCHESTRA Delphi consensus: clinical management of SARS-CoV-2 infection in people with HIV 116
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort 114
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014. 114
Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013 113
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 113
Specific changes in the post-translational regulation of nucleolin in lymphocytes from patients infected with human immunodeficiency virus 112
P128 The role of ancona checkpoint in counseling and facilitating PrEP access through tele-visits 110
Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort 108
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 108
Diagnostica immunologica. 108
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 108
HIV-induced abnormalities in myelopoiesis and their recovery following antiretroviral therapy 107
Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV. 107
Polyclonal serum-free light chains elevation in HIV-infected patients. 106
Incidence and predictors of single drug discontinuation according to the presence of HCV coinfection in HIV patients from the ICONA Foundation Cohort Study. 104
Lo studio fenotipico di linfociti e altre cellule mononucleate. 103
Impaired in-vitro growth of megakaryocytic colonies derived from CD34 cells of HIV-1-infected patients with active viral replicatio 102
LA SIEROLOGIA TIPO-SPECIFICA PER HERPES SYMPLEX TIPO 2 NELLA GESTIONE DEI PAZIENTI HIV POSITIVI 100
PRIMARY BILIARY CHOLANGITIS CASE- FINDING: AN ITALIAN MULTICENTER OBSERVATIONAL STUDY ON PATIENTS WITH INCIDENTAL FINDING OF ANTI- MITOCHONDRIAL ANTIBODIES. 99
Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study 99
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort 98
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 98
HIV among adolescents and young adults in Italy: focus on epidemiological, viro-immunological and treatment characteristics of 689 18-24 year old subjects enrolled in the ICONA Cohort. 98
La ricerca degli anticorpi anti-nucleo non è sempre di facile interpretazione 98
Switch a raltegravir in un paziente con carcinoma a cellule di Merkel e sarcoma di Kaposi. 97
Trends in Mortality in People With HIV From 1999 through 2020: A Multicohort Collaboration 94
La tollerabilità della terapia antiretrovirale come mezzo per la gestione a lungo termine di pazienti complessi: un caso clinico. 92
Risk of clinical events in virologically suppressed people with HIV switching to a two-drug regimen vs. remaining on a three-drug regimen: a target trial emulation 92
Il paziente adulto con immunodeficienza. 90
Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study. 90
Tollerabilità metabolica e durevolezza degli schemi antiretrovirali comprendenti nevirapina. 90
Soluble CD163 in CMV Infected and Uninfected subjects on Virologically-Suppressive Antiretroviral therapy in the ICONA cohort 89
Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians’ and nurses’ points of view 86
ORCHESTRA Delphi consensus: diagnostic and therapeutic management of post-COVID-19 condition in vulnerable populations 86
Il ruolo del Mmg nella diagnosi precoce della malattia da HIV. 80
Infezione da HIV-1. 79
Management of vaccinations in patients with non‐Hodgkin lymphoma 72
L’immunoricostituzione, un paesaggio dai mutevoli confini 70
Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy 66
La riduzione delle interazioni farmacologiche come mezzo per aumentare l’aderenza alla terapia antiretrovirale e garantirne la durability. 61
Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort 49
Self-reported wellbeing and integration levels of migrants with HIV in Italy: a cross-sectional analysis fromthe ICONA cohort 45
Long-term effectiveness of bictegravir-emtricitabine-tenofovir alafenamide (BIC/FTC/TAF) as switch strategy in virologically suppressed people with HIV across age strata: observational data from the ICONA-BIC study 43
HIV infection among adolescents and young adults in Italy: Epidemiology, viro-immunological and treatment outcomes 41
Did the COVID-19 pandemic shift the landscape of late HIV diagnosis? 33
Totale 12.509
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.341
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.341
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022373 0 0 0 0 8 31 30 52 43 48 58 103
2022/20231.153 107 121 75 118 79 230 0 61 277 4 50 31
2023/2024656 105 11 31 85 133 125 18 17 12 13 15 91
2024/20251.541 198 107 56 17 22 60 104 53 418 149 126 231
2025/20265.259 393 387 449 563 467 273 742 455 393 466 455 216
2026/20271.264 251 183 233 592 5 0 0 0 0 0 0 0
Totale 12.552